Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Visual impairment

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    250 result(s) found for: Visual impairment. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2011-002859-34 Sponsor Protocol Number: CRFB002E2402 Start Date*: 2012-04-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, randomized, activecontrolled, 3-arm, multicenter study assessing the efficacy and safety of an individualized, stabilization-criteria-driven PRN dosing regimen w...
    Medical condition: visual impairment due to macular edema secondary to branch retinal occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10015919 - Eye disorders 10025415 Macular oedema PT
    14.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    14.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) SE (Completed) HU (Completed) CZ (Completed) ES (Completed) SK (Completed) GR (Completed) NL (Completed) PT (Completed) PL (Completed) FR (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-002350-31 Sponsor Protocol Number: CRFB002E2401 Start Date*: 2012-02-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, open-label, single arm, multicenter study assessing the efficacy and safety of an individualized, stabilization criteria-driven PRN dosing regimen with 0.5-mg ranibizumab in...
    Medical condition: visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10007972 Central retinal vein occlusion LLT
    14.1 10015919 - Eye disorders 10025415 Macular oedema PT
    14.1 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) SE (Completed) HU (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed) GR (Completed) PT (Completed) NL (Completed) PL (Completed) IT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000183-29 Sponsor Protocol Number: REVISION Start Date*: 2022-03-09
    Sponsor Name:Eberhard-Karls University Tübingen, Med. Fac. rep. by University Hospital and its Commercial Director
    Full Title: Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase III proof-of-co...
    Medical condition: Acute non-arteritic central retinal artery occlusion (CRAO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10007971 Central retinal artery occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005418-20 Sponsor Protocol Number: CRFB002G2302 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven macular edema (ME)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10025415 Macular oedema PT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) GB (Completed) LV (Completed) HU (Completed) CZ (Completed) IE (Completed) ES (Completed) BE (Completed) NL (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-003117-28 Sponsor Protocol Number: EPU-P77 Start Date*: 2014-11-03
    Sponsor Name:
    Full Title: Can Methylphenidate (Ritalin) improve memory and attention in mild cognitive impairment? An EEG study
    Medical condition: memory impairment in patients with Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10027174 Memory impaired LLT
    17.0 10029205 - Nervous system disorders 10027175 Memory impairment PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001836-69 Sponsor Protocol Number: Vort-MCI_001 Start Date*: 2021-09-17
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of Vortioxetine in Mild Cognitive Impairment measured by Functional Magnetic Resonance Imaging
    Medical condition: Mild cognitive impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004613-17 Sponsor Protocol Number: 20110912DME1 Start Date*: 2011-12-01
    Sponsor Name:Inst of Ophtalmology Lund University hospital
    Full Title: The effect of intravitreal injections of Lucentis (ranibizumab) on retinal function in diabetic patients with diabetic macular edema and visual impairment
    Medical condition: Diabetic makula edema with visual impairment
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10012653 Diabetic complications HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021662-30 Sponsor Protocol Number: CRFB002F2301 Start Date*: 2010-11-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12 month, phase III, randomized, double-masked, multi-center, active-controlled study to evaluate the efficacy and safety of two different dosing regimens of 0.5 mg ranibizumab vs. verteporfin PD...
    Medical condition: visual impairment due to choroidal neovascularization secondary to pathologic myopia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10036803 Progressive high (degenerative) myopia LLT
    12.1 10060837 Choroidal neovascularization LLT
    12.1 10047571 Visual impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) LV (Completed) HU (Completed) LT (Completed) FR (Completed) ES (Completed) IT (Completed) AT (Completed) SK (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005417-38 Sponsor Protocol Number: CRFB002G2301 Start Date*: 2013-07-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5mg ranibizumab intravitreal injections in patients with visual impairment due to ...
    Medical condition: Visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10015919 - Eye disorders 10060837 Choroidal neovascularization LLT
    17.0 10015919 - Eye disorders 10047571 Visual impairment PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) IT (Completed) LV (Completed) PT (Completed) HU (Completed) CZ (Completed) ES (Completed) LT (Completed) BE (Completed) GR (Completed) DK (Completed) DE (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002731-26 Sponsor Protocol Number: CRFB002DIT01 Start Date*: 2011-08-26
    Sponsor Name:NOVARTIS FARMA
    Full Title: An open-label, multi-center, expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.
    Medical condition: Diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-005039-94 Sponsor Protocol Number: IC2019-05 Start Date*: 2020-12-08
    Sponsor Name:Institut Curie
    Full Title: RETINO 2018 : Ocular conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome.
    Medical condition: Retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011582-88 Sponsor Protocol Number: 41470956 Start Date*: 2009-05-28
    Sponsor Name:St James Hospital
    Full Title: The differential effects of donepezil and placebo on EEG/ ERP measures and fMRI in mild cognitive impairment and elderly controls
    Medical condition: Amnestic Mild cognitive Impairment (aMCI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022616-39 Sponsor Protocol Number: CRFB002DGB14 Start Date*: 2010-11-30
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: RELIGHT - Ranibizumab treatment of diabetic macular oEdema with bimonthLy monItorinG after a pHase of initial Treatment. A UK, 18-month, prospective, open-label, multicenter, single-arm Phase IIIb ...
    Medical condition: Diabetic Macular Oedema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001031-31 Sponsor Protocol Number: CRTH258BDE01 Start Date*: 2019-10-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A comperative BouBle Masked, Two-Arm, Randomized, MUlticenter, Phase IIb Study analyZing the Efficacy and Safety of BroluciZumab versus Aflibercept in Paients with Visual ImpaiRment due to Diabetic...
    Medical condition: diabetic macular edema
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005045-13 Sponsor Protocol Number: CRFB002EDE20 Start Date*: 2012-04-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, multi-center, 6-month extension study comparing the long-term efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal implan...
    Medical condition: visual impairment due to macular edema following retinal vein occlusion (branch or central)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003891-11 Sponsor Protocol Number: LMT-01-02-18 Start Date*: 2019-07-16
    Sponsor Name:Life Molecular Imaging SA
    Full Title: An Open Label, Single Center Study, to evaluate the Safety and Imaging Characteristics of [18F]PI-2620 as PET Radioligand for Imaging Tau deposition in the brains of subjects with amnestic mild cog...
    Medical condition: Alzheimer's Disease Amnestic Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-004959-39 Sponsor Protocol Number: CRFB002A2405 Start Date*: 2013-05-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-month, phase IIIb, randomized, double-masked, multicenter study assessing the efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional a...
    Medical condition: Visual impairment due to neovascular AMD
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10060837 Choroidal neovascularization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) GB (Prematurely Ended) GR (Completed) SE (Completed) FI (Completed) PT (Completed) HU (Completed) NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-005043-97 Sponsor Protocol Number: 04/MA/003E Start Date*: 2005-06-30
    Sponsor Name:St Mary's NHS Trust
    Full Title: A Pilot study investigating the use of Intravitreal Triamcinolone prior to macular laser for Clinically Significant Diabetic Macular Oedema
    Medical condition: Macular oedema affects 29% of diabetic patients and is the main cause of visual impairment. Previous studies show that diffuse macular oedema carries a particularly poor prognosis despite laser pho...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019795-74 Sponsor Protocol Number: CRFB002D2304 Start Date*: 2010-10-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2 year randomized, single-masked, multicenter, controlled phase IIIb trial assessing the Efficacy and safety of 0.5 mg ranibizumab in two “treat and extend” treatment algorithms vs. 0.5 mg ranibi...
    Medical condition: Diabetic Macular Edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) PT (Completed) GB (Completed) FR (Completed) ES (Completed) HU (Completed) IT (Completed) IE (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003056-21 Sponsor Protocol Number: ReCaLL-2013 Start Date*: 2014-03-19
    Sponsor Name:GWT-TUD GmbH
    Full Title: Evaluation of an additional therapeutic approach to diabetic macular edema by combining standard therapy (intravitreal injection of a VEGF‐inhibitor) with micropulse diode laser treatment in a rand...
    Medical condition: visual impairment due to diabetic macular edema
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 12:53:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA